U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H18F2O2
Molecular Weight 292.3204
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BIFLURANOL

SMILES

CC[C@H]([C@H](C)C1=CC(F)=C(O)C=C1)C2=CC=C(O)C(F)=C2

InChI

InChIKey=RDVXUHOSYIBGBT-ZWNOBZJWSA-N
InChI=1S/C17H18F2O2/c1-3-13(12-5-7-17(21)15(19)9-12)10(2)11-4-6-16(20)14(18)8-11/h4-10,13,20-21H,3H2,1-2H3/t10-,13-/m1/s1

HIDE SMILES / InChI

Molecular Formula C17H18F2O2
Molecular Weight 292.3204
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Bifluranol (brand name Prostarex), a fluorinated bibenzyl anti-androgen was developed as a nonsteroidal estrogen and was studied for the treatment of benign prostatic hyperplasia. Besides, was shown that bifluranol inhibited 17 alpha-hydroxylase/C17-C20 lyase.

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Thirty five patients with bladder outflow obstruction received either Bifluranol 1.5 mg orally, t.d.s. or placebo in a double‐blind trial.
Route of Administration: Oral
Substance Class Chemical
Record UNII
47602X79JF
Record Status Validated (UNII)
Record Version